Arrowhead Research reported $24.38M in Interest Expense on Debt for its fiscal quarter ending in June of 2025.


Interest Expense On Debt Change Date
Agios Pharmaceuticals 3.01M 10.05M Dec/2024
Alnylam Pharmaceuticals USD 40.25M 1.6M Jun/2025
Arrowhead Research USD 24.38M 2.74M Jun/2025
Incyte USD 594K 66K Jun/2025
Ionis Pharmaceuticals USD 19M 0 Jun/2025
Ligand Pharmaceuticals USD 1.15M 286K Jun/2025
Merck USD 305M 8M Jun/2025
Moderna USD 1000K 0 Jun/2025
Novartis USD 289M 19M Jun/2025
Sarepta Therapeutics USD 5.23M 725K Jun/2025
TG Therapeutics USD 6.72M 4.12M Jun/2025
Ultragenyx Pharmaceutical 14.04M 1.48M Jun/2025
Vertex Pharmaceuticals USD 3.7M 900K Jun/2025
Xencor 8.24M 422K Jun/2025